default author photo

Biagio Ricciuti

Harvard University - Dana-Farber Cancer Institute

Boston, MA

United States

SCHOLARLY PAPERS

3

DOWNLOADS

234

TOTAL CITATIONS

1

Scholarly Papers (3)

1.

Impact of Platinum-Based Chemotherapy and CTLA-4 Inhibition on Acquired Resistance to First-Line Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer: A Systematic Review and Reconstructed Individual Patient Data Analysis

Number of pages: 24 Posted: 26 Apr 2025
Università Vita-Salute San Raffaele - San Raffaele Hospital, University of Naples Federico II, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, University of Verona, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, University of Naples Federico II, Manchester Academic Health Sciences Centre - The Christie NHS Foundation Trust, University of Turin - Department of Oncology, Harvard University - Dana-Farber Cancer Institute, Imperial College London, German Centre for Lung Research - Lungen Clinic Grosshansdorf, Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Laboratory of Methodology of Systematic Reviews and Guidelines Production, Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Department of Oncology, AORN dei Colli - Monaldi Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 99 (704,534)

Abstract:

Loading...

acquired resistance, platinum-based chemotherapy, CTLA-4 inhibitors, immunotherapy, non-small cell lung cancer

2.

Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older with Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in Pd-L1 High (≥50%) Patients

Number of pages: 35 Posted: 03 Jan 2025
Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Imperial College London, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, University of California, Los Angeles (UCLA), Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, MD Anderson Cancer Center - Department of Gastroenterology, Hepatology and Nutrition, affiliation not provided to SSRN, University of Kansas - Cancer Center, University of Kansas - University of Kansas Medical Center, Vanderbilt University, Vanderbilt University - Medical Center, Imperial College London, Harvard University - Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute and University of Oklahoma - Stephenson Cancer Center
Downloads 87 (783,685)

Abstract:

Loading...

Non-Small Cell Lung Cancer, immunotherapy, pembrolizumab, Tumor microenvironment, Tumor immunophenotype, Older adults

3.

Fully Automatic Content-Aware Tiling Pipeline for Pathology Whole Slide Images

Number of pages: 17 Posted: 21 Oct 2025
Imperial College London, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, Imperial College London, University of Copenhagen - Copenhagen University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Harvard Medical School and affiliation not provided to SSRN
Downloads 48 (1,086,013)
Citation 1

Abstract:

Loading...

Computational Pathology, Whole Slide Images, Deep learning, Tissue Artifacts, Histology